Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2009

View Archived Issues

Clinical evaluations support further development of PF-00610355 for COPD/asthma

Preliminary phase II data show efficacy of farletuzumab plus platinum/taxane in ovarian cancer

Novartis reports interim results from phase II trial of Cytos Biotechnology's nicotine vaccine

Chugai files application in Japan for Avastin monoclonal antibody in breast cancer

Critical Outcome Technologies reports data from animal studies of COTI-2

GSK reports results from second clinical trial of its Pandemrix H1N1 influenza vaccine

Bevacizumab alone or in combination improves visual acuity in patients with CNV and macular edema

BF-200 ALA nanoemulsion formulation effective in photodynamic therapy for AK lesions

Hydra Biosciences and Cubist sign agreement to develop ion channel drugs for pain

FDA issues complete response letter regarding Amgen's BLA for Prolia

Genentech and Biogen Idec receive complete response from the FDA for sBLA for Rituxan

Estradiol valerate/dienogest reduces heavy/prolonged menstrual bleeding

FDA issues complete response letter regarding Novartis' QAB-149 in COPD

Gene modified cellular vaccine shows promise in metastatic breast cancer models

Biogen Idec and Biovitrum to initiate registrational trial of rFIXFc in hemophilia B patients

FDA approves Boehringer Ingelheim's Twynsta for hypertension treatment

Almirall completes phase II study and enrollment in phase III study of Eklira

FDA issues complete response letter regarding Endo's Fortesta NDA for hypogonadism

Repligen completes patient treatment in phase III RG-1068/MRI imaging trial

Preclinical data on the allosteric AMPA modulator, EPAT, disclosed at Neuroscience 2009

TR-L-382 shows promising analgesic activity in mouse models of neuropathic pain

MSD-9 reduces Abeta1-42 burden in the hippocampus of AD mouse model

Sanofi-aventis claims SGLT-2 inhibitors for the treatment of type 1 and type 2 diabetes

Vichem Chemie presents novel selective EGFR inhibitors as oncolytics

HIF-PH inhibitors in early development at FibroGen described in recent patent

FDA approves Votrient for advanced renal cell cancer